Trastuzumab duocarmazine, also known as [vic-]trastuzumab duocarmazine or SYD985, is an experimental antibody-drug conjugate (ADC) designed to treat HER2-positive cancers. It combines trastuzumab, a monoclonal antibody targeting the HER2 receptor, with duocarmazine, a powerful cytotoxic drug. This design delivers the drug directly to HER2-expressing cancer cells, enhancing effectiveness while reducing side effects.
Key Features
- Targeted Therapy: Binds to HER2, a protein overexpressed in certain breast and solid tumors.
- Mechanism of Action: After binding to HER2, the ADC enters cancer cells and releases the cytotoxic drug, killing the cells.
- Precision Treatment: Focuses on cancer-specific proteins, minimizing harm to healthy tissues.
Clinical Development
Trastuzumab duocarmazine has shown promise in clinical trials for HER2-positive breast cancer, improving progression-free survival. However, it has been associated with some side effects, including ocular toxicity, which led to treatment discontinuation in some patients.
Applications
- Breast Cancer: Treats HER2-positive metastatic breast cancer.
- Other Solid Tumors: Explored for HER2-positive cancers in other tissues.
Trastuzumab duocarmazine offers a targeted approach to treating HER2-expressing cancers, aiming for effective outcomes with fewer side effects.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.